Navigation Links
Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
Date:11/6/2007

/p>

indicated that a future New Drug Application filing for this product

candidate could be eligible to receive priority review. The company

plans to initiate a Phase II clinical trial in the fourth quarter of

2007.

-- Interim data have been obtained from two single dose studies, one in

healthy volunteers and one in epilepsy patients, of JZP-4, a product

candidate for the treatment of partial epilepsy and bipolar disorder.

The data from both of these studies indicate biological activity in

human epilepsy models. A single dose study of a controlled-release

formulation of JZP-4 is underway, and is expected to complete in the

fourth quarter of 2007. Jazz Pharmaceuticals plans to initiate

Phase II clinical trial activities for JZP-4 by the end of 2007.

-- A second pharmacokinetic study of JZP-7, a product candidate for the

treatment of restless legs syndrome, was initiated in the third quarter

of 2007, and Jazz Pharmaceuticals expects top line results from that

study in the second quarter of 2008.

-- In August 2007, the U.S. Patent and Trademark Office (USPTO) awarded

Jazz Pharmaceuticals a new U.S. patent (No. 7,262,219) titled

"Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate

Salt for the Treatment of Narcolepsy." This Xyrem patent is now listed

in the FDA's Orange Book.

Jazz Pharmaceuticals will host an investor conference call and live audio webcast to discuss its quarterly results on November 6, 2007 at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The live webcast and press release may be accessed on Jazz Pharmaceuticals' website at http://www.JazzPharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that m
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... optical imaging device developed at Cedars-Sinai can provide ... the brain and are a classic sign of ... conducting a clinical trial in Australia. , The ... an oral presentation at the Alzheimer,s Association International ... invited by conference organizers to participate in a ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A ... & Schulte LLC to provide consumers with the most ... accompany use of the blood-thinning medication, as well as ... pending in courts around the country. The law firm ... may have suffered from life-threatening internal bleeding and related ...
(Date:7/13/2014)... MI (PRWEB) July 13, 2014 If Dr. ... program he has just launched at http://www.HealthYourself101.com will ... visceral obesity. , Power has set out to provide ... ill effects that’s actually – dare we say it? – ... program,” says Power, “aims to engage the remote learner – ...
(Date:7/12/2014)... to the new market research report "Security and Surveillance ... - Global Forecasts and Analysis to 2014 - 2020", ... estimated to be $6.08 billion in 2014 and are ... $8.61 billion by 2020. , Browse more than 93 ... pages and in-depth TOC on "Security and Surveillance Radar ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The Passenger ... million in 2013 to $20,341.36 million by 2019, at ... 2013 and 2019. , The public transport infrastructure in ... is also available in almost every corner of the ... the interest of public transport service providers are driving ...
Breaking Medicine News(10 mins):Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4
... "an illegal alien mother is not a deemed newborn" ... undocumented mothers of new// borns must apply for Medicaid. ... automatic for all babies whose mothers received emergency Medicaid coverage ... could leave babies without access to essential medical care such ...
... the eye cancer retinoblastoma has been developed by scientists ... a mouse model to cause a remarkable reduction in ... effects common with standard chemotherapy. In addition the treatment ... breast, lung, prostate and colon cancer, and is simple ...
... chronic obstructive pulmonary disease (COPD) attempt to repair damaged elastic ... is in contradiction with the conventional wisdom on the capabilities ... could pave the way to develop a drug to 'turn ... alveoli. ,The study "Evidence for attempted regional elastic ...
... human beings has found that concerns over the rise in ... still held in esteem and very much in demand. The ... ,The research has gathered details from 59 countries, which ... of live-in relationships and marriage figured on their wish-list. ...
... by more action and less talk according to opposition parties, ... on drinks. ,Leading doctors have launched a new ... raise awareness of alcohol-related health problems and push for action ... Conservative parties say the Executive needs to deal with the ...
... been found to have more sugar and fat than ... ,While each of these f 20 well-known bars, mostly ... sugar" under the Food Standards Agency's traffic light labeling ... more sugar (10g) than a chocolate Penguin bar (9.7g).,according ...
Cached Medicine News:Health News:Revolutionary Eye Cancer Treatment 2Health News:Revolutionary Eye Cancer Treatment 3Health News:Revolutionary Eye Cancer Treatment 4Health News:Lungs repair themselves 2Health News:Alcohol Abuse Must be solved with Action 2Health News:Cereal Bars Slammed for More Sugar Than Sweet Snacks 2
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... NORRITON, Pa., Aug. 15, 2011 Tengion, Inc. (Nasdaq: ... Jorkasky, M.D., who recently joined Endo Pharmaceuticals (Nasdaq: ... Medical Officer, to its Board of Directors. ... at Quaker BioVentures, is stepping down from the Tengion Board ...
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a developer ... its second quarter 2011 financial results for the period ended June ... second quarter. Updates since the beginning of the ... Multiple Sclerosis (MS) As ...
Cached Medicine Technology:Tengion Appoints Diane Jorkasky, M.D., to its Board of Directors 2Adeona Reports Second Quarter 2011 Financial Results 2Adeona Reports Second Quarter 2011 Financial Results 3Adeona Reports Second Quarter 2011 Financial Results 4Adeona Reports Second Quarter 2011 Financial Results 5Adeona Reports Second Quarter 2011 Financial Results 6Adeona Reports Second Quarter 2011 Financial Results 7Adeona Reports Second Quarter 2011 Financial Results 8Adeona Reports Second Quarter 2011 Financial Results 9
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: